Selective Serotonin Reuptake Inhibitors: Pharmacology, Administration, and Side Effects

Introduction and Indications

Selective serotonin reuptake inhibitors (SSRIs) are a class of medications frequently utilized as first-line antidepressants due to their established efficacy, favorable tolerability, and general safety in the event of an overdose. The primary SSRIs discussed include:

  • Citalopram

  • Escitalopram

  • Fluoxetine

  • Fluvoxamine

  • Paroxetine

  • Sertraline

Beyond unipolar depression, SSRIs are indicated for a spectrum of conditions:

  • Anxiety disorders

  • Eating disorders

  • Menopausal hot flashes

  • Obsessive-compulsive and related disorders

  • Posttraumatic stress disorder (PTSD)

  • Premature ejaculation

  • Premenstrual dysphoric disorder (PMDD)

  • Somatic symptom disorder

Pharmacology: Structure and Dynamics

Chemical Structure SSRIs vary significantly in chemical structure. Paroxetine and sertraline exist as single isomers. In contrast, citalopram and fluoxetine are racemic mixtures consisting of two superimposable mirror-image stereoisomers. Escitalopram is specifically the SS-isomer of citalopram (SS-citalopram) and is the stereoisomer that more potently inhibits serotonin reuptake.

Pharmacodynamics The primary mechanism involves increasing serotonergic activity by selectively inhibiting the presynaptic serotonin reuptake pump. Serotonin, known as 55-hydroxytryptamine or 5−HT5-HT, is an indoleamine neurotransmitter released from the brainstem raphe nuclei. Brain neurotransmission involves at least 1414 different types of pre- and postsynaptic serotonin receptors.

Key dynamic features include:

  • Reuptake Inhibition: SSRIs decrease the action of the reuptake pump by as much as 90%90\%, increasing the duration serotonin remains in the synapse and increasing postsynaptic receptor occupancy.

  • Target Selectivity: They have relatively little affinity for other receptors (alpha-adrenergic, histaminic, or cholinergic), which accounts for their benign side effect profile relative to older antidepressants. Paroxetine is a minor exception, showing weak antagonism for cholinergic receptors.

  • Downstream Effects: Therapeutic response is not solely due to reuptake inhibition, which occurs shortly after administration. Full clinical effect often requires 33 to 88 weeks (or more), likely involving downstream changes such as increased production of neuroprotective proteins (e.g., brain-derived neurotrophic factor, Bc1-2) and modification of serotonergic receptor subtypes over weeks of treatment.

Pharmacokinetics and Drug-Drug Interactions

Absorption and Distribution SSRIs are well-absorbed in the gastrointestinal tract, reaching peak plasma levels within 11 to 88 hours. They are lipophilic, protein-bound, and widely distributed throughout the body including the brain. Food generally does not affect absorption, with the exception of sertraline, which is absorbed more rapidly when taken with food.

Metabolism and Elimination Metabolism occurs primarily in the liver. All SSRIs except fluvoxamine produce pharmacologically active metabolites. Fluoxetine is unique as it yields norfluoxetine, which potently inhibits serotonin reuptake and possesses antidepressant activity.

Elimination half-lives are as follows:

  • Citalopram: 2424 to 36 hours36\,hours

  • Escitalopram: 2727 to 32 hours32\,hours

  • Fluoxetine: 44 to 6 days6\,days (Active metabolite norfluoxetine: 44 to 16 days16\,days)

  • Fluvoxamine: 15 hours15\,hours

  • Paroxetine: 24 hours24\,hours

  • Sertraline: 26 hours26\,hours

Hepatic Enzyme Inhibition (CYP450) SSRIs vary in their inhibition of cytochrome P450 enzymes, which can lead to significant drug-drug interactions:

  • Fluoxetine: Potent inhibitor of CYP2D6; moderate inhibitor of CYP2C19.

  • Fluvoxamine: Potent inhibitor of CYP1A2; moderate inhibitor of CYP2C19.

  • Paroxetine: Potent inhibitor of CYP2D6.

  • Citalopram and Escitalopram: Show the least inhibition of liver enzymes and are preferred when drug-drug interactions are a primary concern.

Notable Clinical Interactions

  • Tamoxifen: Fluoxetine and paroxetine (CYP2D6 inhibitors) can interfere with the conversion of the prodrug tamoxifen to its active metabolite for breast cancer treatment. Use of alternative antidepressants is preferred.

  • Prodrug Opioids: CYP2D6 inhibitors can prevent the conversion of codeine, hydrocodone, and tramadol into their active forms (e.g., morphine). A 9-year study showed worse postoperative pain control in patients taking SSRIs with prodrug opioids vs. non-prodrug opioids like morphine or fentanyl.

  • Serotonin Syndrome: Co-administration with other serotonergic agents (e.g., MAOIs, lithium, SNRIs, St. John's wort) increases the risk of serotonin syndrome.

Clinical Administration: Dosing and Response

General Principles SSRIs are contraindicated in patients with hypersensitivity or those who have taken a monoamine oxidase inhibitor (MAOI) within the previous 2 weeks2\,weeks. Clinicians should discuss side effects, response time, and the risks of abrupt discontinuation (discontinuation syndrome: dysphoria, dizziness, GI distress, fatigue).

Equipotent Initial Dosing for Depression

  • Citalopram: 20 mg/day20\,mg/day (Max 40 mg/day40\,mg/day in most; 20 mg/day20\,mg/day in patients >60 years>60\,years or with hepatic impairment).

  • Escitalopram: 10 mg/day10\,mg/day (Max 20 mg/day20\,mg/day).

  • Fluoxetine: 20 mg/day20\,mg/day (Max 80 mg/day80\,mg/day).

  • Fluvoxamine: Starting 50 mg/day50\,mg/day; maintain at 100100 to 200 mg/day200\,mg/day (Divided doses if >100 mg>100\,mg).

  • Paroxetine: 20 mg/day20\,mg/day (Max 50 mg/day50\,mg/day).

  • Sertraline: 50 mg/day50\,mg/day (Max 200 mg/day200\,mg/day; doses up to 300 mg300\,mg have been used).

Titration and Timing

  • Doses are generally taken once daily, usually in the morning to minimize insomnia.

  • Adjustment: Evaluate response for 22 to 6 weeks6\,weeks at the minimum therapeutic dose before adjusting. Increases typically occur every 11 to 4 weeks4\,weeks.

  • Patients with comorbid anxiety may require starting at half the usual dose to improve tolerability.

Response Time Statistics

  • STAR*D Study: In 28762876 outpatients, mean time to response for citalopram was 6 weeks6\,weeks; 56%≥8 weeks56\% ≥ 8\,weeks

  • Fluoxetine Study: In 384384 outpatients, the cumulative probability of response was 56%56\% at week 2, 80%80\% at week 4, and 90%90\% at week 6.

Medical Tests and Plasma Levels

No mandatory medical tests are required prior to starting an SSRI. Serum concentrations are not standard practice but may be useful for:

  • Validating safety when starting an MAOI (waiting 55 elimination half-lives is the standard alternative).

  • Monitoring rapid metabolizers, treatment-resistant cases, or specific populations (children, elderly, pregnant, or patients with hepatic disease).

Reference Ranges for Plasma Levels

  • Citalopram: 5050 to 110 ng/mL110\,ng/mL

  • Escitalopram: 1515 to 80 ng/mL80\,ng/mL

  • Fluoxetine + Norfluoxetine: 120120 to 500 ng/mL500\,ng/mL

  • Fluvoxamine: 6060 to 230 ng/mL230\,ng/mL

  • Paroxetine: 2020 to 65 ng/mL65\,ng/mL

  • Sertraline: 1010 to 150 ng/mL150\,ng/mL

Safety Profile: Adverse Effects and Warnings

Commonly Reported Side Effects

  • Nausea: Most common; mitigated by starting at low doses and taking with food. More frequent with paroxetine and fluvoxamine.

  • Sexual Dysfunction: High incidence (addressed in separate literature).

  • Weight Change: Short-term effects vary by medication (22 to 3 months3\,months); paroxetine is most associated with weight gain.

  • CNS Effects: Insomnia, somnolence, headache, tremor, activation (fluoxetine/sertraline), and sedation (paroxetine/fluvoxamine).

Suicide Risk Evidence on whether antidepressants increase suicidality is inconclusive. Age-specific risk nuances suggest:

  • Age 1818 to 24 years24\,years: Slight increase in risk.

  • Age 2525 to 30 years30\,years: No effect.

  • Age 31+ years31+ \,years: Potentially lowers risk.

Cardiac Effects (QTc Prolongation) Citalopram causes dose-dependent prolongation of the corrected QT interval, potentially leading to Torsade de Pointes.

  • FDA Finding for Citalopram: 60 mg/day60\,mg/day caused 18.5 ms18.5\,ms prolongation; 20 mg/day20\,mg/day caused 8.5 ms8.5\,ms.

  • FDA Warning: Max dose 40 mg40\,mg; limit to 20 mg20\,mg if age >60>60 or hepatic impairment. Avoid in those with congenital long QT, bradycardia, or hypokalemia.

  • Escitalopram: At 30 mg/day30\,mg/day, QTc increase was 10.7 ms10.7\,ms. FDA did not issue a mandatory warning, though some reports suggest caution.

  • Safest for Heart Disease: Sertraline and fluoxetine are often cited as having the lowest risk of QTc prolongation.

Bleeding Risk SSRIs inhibit the serotonin transporter in platelets, reducing platelet aggregation.

  • Observational risk: Odds ratio (OROR) for serious bleeding is 1.41.4.

  • GI Bleeding: OROR increases to 1.61.6 in SSRI users and as high as 3.73.7 to 4.34.3 when combined with NSAIDs.

  • Management: PPIs are sometimes prescribed when SSRIs are used with NSAIDs to reduce GI risk.

Hyponatremia (SIADH) Primarily occurs in adults >65 years>65\,years, especially within the first 2 weeks2\,weeks of treatment (median 11 daysmedian\,11\,days).

  • Comparison of incidence rate ratios (IRRIRR): Citalopram (7.87.8), Fluoxetine (5.65.6), Paroxetine (6.26.2), Sertraline (4.54.5).

Serotonin Syndrome and Overdose

Serotonin Syndrome A potentially lethal overstimulation of serotonin receptors.

  • Symptoms: Anxiety, delirium, diaphoresis, tachycardia, hyperthermia, tremor, hyperreflexia, and muscle rigidity.

  • Management: Discontinue all serotonergic agents. Supportive care with oxygen and IV fluids. Use benzodiazepines (lorazepam 11 to 2 mg2\,mg IV) for agitation and neuromuscular symptoms. If benzodiazepines fail, administer cyproheptadine (12 mg12\,mg initial adult dose).

Overdose Management SSRI overdoses are rarely fatal unless involving extremely large quantities or coingestion of other substances.

  • Symptoms: Drowsiness, tremor, and vomiting.

  • Citalopram Toxicity: Citalopram is considered the most lethal SSRI in overdose (Poison Center data shows mortality risk 3×3\times higher than paroxetine and 5×5\times higher than fluoxetine/sertraline due to QTc effects).

  • Treatment Protocol: Activated charcoal (1 g/kg1\,g/kg; standard 50 g50\,g for adults). Treat seizures with lorazepam. Treat prolonged QRS (conduction delay\text{conduction delay}) with sodium bicarbonate (11 to 2 meq/kg2\,meq/kg IV). Treat Torsades de Pointes with magnesium sulfate (2 g2\,g IV).